Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cordyceps cicadae aqueous extract (CCE) is a botanical extract derived from the entomopathogenic fungus *Cordyceps cicadae* (Miq.) Massee, which has a long history of use in traditional Chinese medicine. The extract is a complex mixture of bioactive compounds, including polysaccharides, nucleosides (such as cordycepin and adenosine), mannitol, and polyphenols. Preclinical research suggests that CCE exhibits significant antioxidant, anti-inflammatory, and immunomodulatory activities. Specifically, it has been shown to reduce intraocular pressure in models of glaucoma by enhancing the activity of antioxidant enzymes like catalase and superoxide dismutase. Additionally, it promotes hyaluronan synthesis in skin fibroblasts, indicating potential for cosmetic and dermatological applications in skin aging. It is also being investigated for its potential benefits in chronic kidney disease and cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cordyceps cicadae aqueous extract.